Phaseline

Targets › RPS6

RPS6 (Small ribosomal subunit protein eS6): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Other, Oncology; next expected readout Jun 2027.

Component of the 40S small ribosomal subunit. Plays an important role in controlling cell growth and proliferation through the selective translation of particular classes of mRNA. Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. (UniProt, P62753)

Open in Phaseline: the race on RPS6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eloxx PharmaceuticalsElx-02
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 2Alport Syndrome, X-LinkedJun 2027
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ataluren
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 1Colorectal Cancer–

Conditions

Alport Syndrome, X-Linked (1) Colorectal Cancer (1)

Modalities

small molecule (1), antibody (1)

Companies

Eloxx Pharmaceuticals (1) Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)

Related targets

RPSA (2) RPS27 (2) RPS2 (2) RPS3 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.